JP2014528482A5 - - Google Patents

Download PDF

Info

Publication number
JP2014528482A5
JP2014528482A5 JP2014535928A JP2014535928A JP2014528482A5 JP 2014528482 A5 JP2014528482 A5 JP 2014528482A5 JP 2014535928 A JP2014535928 A JP 2014535928A JP 2014535928 A JP2014535928 A JP 2014535928A JP 2014528482 A5 JP2014528482 A5 JP 2014528482A5
Authority
JP
Japan
Prior art keywords
benzo
methyl
amino
thiazol
cyclohexanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014535928A
Other languages
English (en)
Japanese (ja)
Other versions
JP6162130B2 (ja
JP2014528482A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/059983 external-priority patent/WO2013056070A2/en
Publication of JP2014528482A publication Critical patent/JP2014528482A/ja
Publication of JP2014528482A5 publication Critical patent/JP2014528482A5/ja
Application granted granted Critical
Publication of JP6162130B2 publication Critical patent/JP6162130B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014535928A 2011-10-14 2012-10-12 Iii型受容体チロシンキナーゼの調節因子としての複素環式化合物及びその使用 Expired - Fee Related JP6162130B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161547637P 2011-10-14 2011-10-14
US61/547,637 2011-10-14
US201261638990P 2012-04-26 2012-04-26
US61/638,990 2012-04-26
PCT/US2012/059983 WO2013056070A2 (en) 2011-10-14 2012-10-12 Heterocyclic compounds and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2014528482A JP2014528482A (ja) 2014-10-27
JP2014528482A5 true JP2014528482A5 (enExample) 2015-12-03
JP6162130B2 JP6162130B2 (ja) 2017-07-12

Family

ID=47116440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535928A Expired - Fee Related JP6162130B2 (ja) 2011-10-14 2012-10-12 Iii型受容体チロシンキナーゼの調節因子としての複素環式化合物及びその使用

Country Status (29)

Country Link
US (3) US8952058B2 (enExample)
EP (1) EP2766359B9 (enExample)
JP (1) JP6162130B2 (enExample)
KR (1) KR102066297B1 (enExample)
CN (1) CN104066730B (enExample)
AR (1) AR089568A1 (enExample)
AU (1) AU2012322095B2 (enExample)
BR (1) BR112014009006B8 (enExample)
CA (1) CA2851155C (enExample)
CY (1) CY1117745T1 (enExample)
DK (1) DK2766359T5 (enExample)
ES (1) ES2586527T3 (enExample)
HR (1) HRP20160744T2 (enExample)
HU (1) HUE027745T4 (enExample)
IL (1) IL231927A (enExample)
IN (1) IN2014CN03597A (enExample)
MX (1) MX368081B (enExample)
MY (1) MY167575A (enExample)
PH (2) PH12014500794B1 (enExample)
PL (1) PL2766359T3 (enExample)
PT (1) PT2766359T (enExample)
RS (1) RS54936B1 (enExample)
RU (1) RU2648997C2 (enExample)
SG (1) SG11201401236XA (enExample)
SI (1) SI2766359T1 (enExample)
SM (1) SMT201600223B (enExample)
TW (2) TWI605043B (enExample)
WO (1) WO2013056070A2 (enExample)
ZA (1) ZA201402549B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014031445A1 (en) * 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydropyran derivatives
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
IL311677B2 (en) 2014-01-13 2025-06-01 Aurigene Oncology Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
CR20180109A (es) * 2015-07-20 2018-05-03 Genzyme Corp Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r)
US20190263799A1 (en) * 2015-12-14 2019-08-29 Zenith Epigenetics Ltd. 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
WO2017176792A1 (en) * 2016-04-04 2017-10-12 Massachusetts Institute Of Technology Methods of preventing or reducing a fibrotic response using csf 1r inhibitors
JP2018058822A (ja) 2016-08-03 2018-04-12 ファイザー・インク ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用
US10899741B2 (en) 2016-11-14 2021-01-26 Jiangsu Hengrui Medicine Co., Ltd. 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof
EP3570836A4 (en) 2017-01-23 2020-08-19 The University of Hawaii 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE STAT3 INHIBITORS
CN120267671A (zh) * 2017-03-31 2025-07-08 奥锐金肿瘤有限公司 用于治疗血液病的化合物和组合物
JP7414282B2 (ja) 2017-12-07 2024-01-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Nsdファミリー阻害物質及びそれによる治療の方法
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
WO2021047677A1 (zh) * 2019-09-12 2021-03-18 中国科学院上海药物研究所 一类irak4激酶抑制剂及其制备和应用
CN112479897B (zh) * 2020-12-07 2022-11-04 万华化学集团股份有限公司 一种1,3-环己二甲胺的制备工艺
US11530216B2 (en) 2020-12-23 2022-12-20 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors
CA3214747A1 (en) 2021-04-08 2022-10-13 Reinhard Von Roemeling Combination therapies for the treatment of cancer
CN117384110A (zh) * 2023-10-16 2024-01-12 奥盖尼克材料(苏州)有限公司 一种2-氨基苯并恶唑-6-腈的制备方法

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4104385A (en) 1976-08-19 1978-08-01 Sterling Drug Inc. Cyclic alkylidenyl N-[6-(amino)-3-pyridazinyl]aminomethylenemalonates
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2687932A1 (fr) 1992-02-27 1993-09-03 Oreal Dispersion huile-dans-l'eau susceptible de former des films composites.
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
NZ503491A (en) * 1997-11-10 2002-08-28 Bristol Myers Squibb Co 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors
NZ505651A (en) 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
PL357099A1 (en) * 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
JP4583751B2 (ja) * 2001-06-06 2010-11-17 アベンティス・フアーマ・リミテッド 炎症性疾患の治療に使用するための置換されたテトラヒドロイソキノリン
US7112435B1 (en) 2002-08-07 2006-09-26 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
WO2003087089A1 (en) * 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
JPWO2005040135A1 (ja) 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
DE10349587A1 (de) * 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
AR046770A1 (es) 2003-12-18 2005-12-21 Tibotec Pharm Ltd Derivados bencimidazol 5- o 6-substituidos como inhibidores de la replicacion del virus sincitial respiratorio
AR046959A1 (es) 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005100373A2 (en) * 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited Monosaccharide derivatives as anti-cancer and anti-inflammatory agents
US6969498B1 (en) * 2004-05-07 2005-11-29 Riley Medical, Inc. Surgical instrument bracket assembly
JP2006070014A (ja) 2004-08-04 2006-03-16 Hisamitsu Medical Kk 2−アミノベンゾチアゾール誘導体
AU2006260969B2 (en) 2005-06-20 2011-11-17 Janssen Sciences Ireland Uc 1- ( 2-amino-3- (substituted alkyl)-3H-benzimidazolylmethyl) -3-substituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus
WO2007022305A2 (en) 2005-08-16 2007-02-22 Pharmacopeia, Inc. 2-aminoimidazopyridines for treating neurodegenerative diseases
KR101449057B1 (ko) * 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
NZ570524A (en) * 2006-03-28 2011-08-26 High Point Pharmaceuticals Llc Benzothiazoles having histamine H3 receptor activity
JP5415264B2 (ja) 2006-06-30 2014-02-12 ドイスコベルク コーポレーション 検出可能な核酸タグ
JP2010522765A (ja) 2007-03-28 2010-07-08 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼとしてのイミダゾ[1,2−a]ピリジン化合物
AU2008254425A1 (en) * 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
US20100261679A1 (en) * 2007-10-18 2010-10-14 James Sutton CSF-1R, Inhibitors, Compositions, and Methods of Use
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
US8309577B2 (en) * 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
HUE035798T2 (en) 2008-11-03 2018-05-28 Syntarga Bv CC-1065 analogues and conjugates
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8513291B2 (en) 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
SG10201505997TA (en) 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases

Similar Documents

Publication Publication Date Title
RU2014119244A (ru) Гетероциклические соединения и способы их использования
AU2018201903B2 (en) SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
AU2018374456B2 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
KR101750667B1 (ko) Syk 억제제
AU2010249380B2 (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
JP2020514267A5 (enExample)
AU2011344001A1 (en) Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
JP2021503004A5 (enExample)
RU2016140338A (ru) Азаспиро производные в качестве антагонистов trpm8
JP2024096702A (ja) モノアシルグリセロールリパーゼ調節因子
ME02330B (me) Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspir0[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora
ME02802B (me) P2x7 modulatori
JP2021501806A5 (enExample)
NZ737297A (en) Bicyclic lactams and methods of use thereof
NZ737297B2 (en) Bicyclic lactams and methods of use thereof
AU2015205858A1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors